سعر سكيمبليكس 40 مجم 60 قرص 2026

Scemblix (asciminib) 40 mg film-coated tablets, pack of 60, by Novartis; a BCR::ABL1 tyrosine kinase inhibitor (STAMP inhibitor binding the ABL myristoyl pocket) for Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase.

• Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in chronic phase (US accelerated approval based on major molecular response rate)Population: AdultsDailyMed (U.S. National Library of Medicine)
• Previously treated Ph+ CML in chronic phasePopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Ph+ CML in chronic phase with the T315I mutationPopulation: AdultsDailyMed (U.S. National Library of Medicine)

• Most common (>=20%) in the pooled population: musculoskeletal pain, rash, fatigue, upper respiratory tract infection, headache, abdominal pain, arthralgia and diarrhoea.International label, same product · DailyMed (U.S. National Library of Medicine)
• Common laboratory abnormalities include decreased lymphocytes, leukocytes, platelets, neutrophils, haemoglobin and corrected calcium, and increased lipase, cholesterol, triglycerides, uric acid, ALT and alkaline phosphatase.International label, same product · DailyMed (U.S. National Library of Medicine)

• None (US label).International label, same product · DailyMed (U.S. National Library of Medicine)

• Myelosuppression: thrombocytopenia, neutropenia and anaemia occur; perform CBC every 2 weeks for the first 3 months then monthly or as clinically indicated, and withhold, reduce or discontinue by severity.International label, same product · DailyMed (U.S. National Library of Medicine)
• Pancreatic toxicity: pancreatitis and asymptomatic lipase/amylase elevation; check lipase and amylase monthly (more often with a history of pancreatitis) and evaluate abdominal symptoms.International label, same product · DailyMed (U.S. National Library of Medicine)
• Hypertension: monitor and treat; withhold, reduce or discontinue for grade 3 or higher hypertension.International label, same product · DailyMed (U.S. National Library of Medicine)

• Strong CYP3A4 inhibitorsIncrease asciminib exposure; closely monitor for adverse reactions at the 200 mg twice-daily dose.DailyMed (U.S. National Library of Medicine)
• Itraconazole oral solution containing hydroxypropyl-beta-cyclodextrinDecreases asciminib exposure and may reduce efficacy; avoid at all doses.DailyMed (U.S. National Library of Medicine)
• Strong CYP3A4 inducersDecrease asciminib exposure.DailyMed (U.S. National Library of Medicine)

• Based on animal studies and its mechanism of action, asciminib can cause embryo-fetal harm; there are no human data. In rats and rabbits it caused malformations (including cardiac defects and cleft palate), embryo-fetal deaths and growth changes at exposures equal to or below human exposure.International label, same product · DailyMed (U.S. National Library of Medicine)
• Verify pregnancy status before starting; females of reproductive potential should use effective contraception during treatment and for 1 week after the last dose. Asciminib may impair female fertility (reversibility unknown).International label, same product · DailyMed (U.S. National Library of Medicine)
• No data on presence in human milk; advise women not to breastfeed during treatment and for 1 week after the last dose.International label, same product · DailyMed (U.S. National Library of Medicine)

• Asciminib: Inhibits the ABL1 kinase activity of the BCR::ABL1 fusion protein by binding to the ABL myristoyl pocket; active in vitro and in animal models against wild-type BCR::ABL1 and several mutant forms including T315I (US label).